Beta Bionics Under Investigation, Stock Plummets

Written by Emily J. Thompson, Senior Investment Analyst

Source: Globenewswire

Updated: 3d ago

0mins

BBNX-1.21%

Should l Buy BBNX?

Source: Globenewswire

Investigation Launched: Pomerantz LLP is investigating whether Beta Bionics, Inc. has engaged in securities fraud or other unlawful business practices, indicating potential legal risks that could undermine investor confidence.
Declining Financial Performance: Beta Bionics reported a 36% year-over-year increase in new patient starts for Q4 2026, significantly lower than the 68% increase in the previous quarter, reflecting a slowdown in growth that may impact future revenue expectations.
Stock Price Plummet: On January 9, 2026, Beta Bionics' stock price fell by $11.85, or 37.03%, closing at $20.15, signaling heightened market concerns over the company's financial health and potentially prompting investor sell-offs.
Legal Background: Pomerantz LLP, a prominent securities class action law firm with over 85 years of experience, is dedicated to protecting investor rights; unfavorable investigation outcomes could lead to large-scale class action lawsuits, further affecting the company's reputation and stock price.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy BBNX?" and start using high-conviction signals backed by rigorous historical data.

BBNX

$13.08+Infinity%1D

Analyst Views on BBNX

Wall Street analysts forecast BBNX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBNX is 32.00 USD with a low forecast of 28.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Analyst Rating

5 Buy

2 Hold

0 Sell

Moderate Buy

Current: 13.240

Low

28.00

Averages

32.00

High

40.00

Current: 13.240

Low

28.00

Averages

32.00

High

40.00

Stifel

Buy

downgrade

$31 -> $25

2026-02-04

New

Reason

Stifel

Price Target

$31 -> $25

AI Analysis

2026-02-04

New

downgrade

Buy

Reason

Stifel lowered the firm's price target on Beta Bionics to $25 from $31 and keeps a Buy rating on the shares as part of the firm's 2026 overview note for the dental, diabetes, and aesthetics sectors.

Truist

Buy

downgrade

$37 -> $25

2026-02-02

New

Reason

Truist

Price Target

$37 -> $25

2026-02-02

New

downgrade

Buy

Reason

Truist lowered the firm's price target on Beta Bionics to $25 from $37 but keeps a Buy rating on the shares after the company disclosed FDA Warning Letter on Friday related to "deficiencies in responses" to the FDA's Form 483. The operational risk will be minimal, though this is still a negative headline at a time the diabetes sector is out-of-favor and Beta Bionics specifically is "on its heels" after its negative Q4 pre-announcement, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BBNX

Unlock Now

About BBNX

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Faruqi & Faruqi Investigates Beta Bionics for Investor Losses

3 days agoGlobenewswire

Investor Loss Alert: Faruq & Faruqi is investigating Beta Bionics after its stock plummeted approximately 37% on January 9, 2026, primarily due to the company's expectation of fewer patient starts in Q4 than analysts estimated, resulting in significant losses for investors.
Legal Rights Consultation: Securities Litigation Partner Josh Wilson encourages investors who suffered significant losses in Beta Bionics to contact him directly to discuss their legal rights and potential claims, highlighting the firm's commitment to protecting investor interests.
Company Disclosure Issues: The investigation focuses on whether Beta Bionics issued misleading statements or failed to disclose information pertinent to investors, which could impact investor decision-making and the stability of the company's stock price.
Law Firm Background: Since its founding in 1995, Faruqi & Faruqi has recovered hundreds of millions of dollars for investors, showcasing its expertise and successful track record in securities law, which further enhances investor confidence in the ongoing investigation.